Neil Bodick, COO of Chorus – Eli Lilly & Co. to Give Plenary Keynote Address at 3rd Modern Drug Discovery & Development Summit
COO of Chorus, Eli Lilly & Co. announced as Plenary Keynote Speaker for the 3rd Modern Drug Discovery & Development Summit (M3D).
Monrovia, CA, October 13, 2007 --(PR.com)-- Neil Bodick, Chief Operating Officer, Chorus, Lilly Research Laboratories at Eli Lilly and Company is one of four plenary keynote presenters at GTCbio’s 3rd Modern Drug Discovery and Development Summit (M3D) on November 28-30, 2007 at the Hyatt Regency San Francisco Airport.
At M3D, Bodick will discuss one of Eli Lilly’s business units, Chorus, and its experience in early phase drug development. Chorus, a part of Lilly Research Laboratories, develops new chemical entities from candidate selection to clinical Proof of Concept (PoC), conducting minimal amount of work to demonstrate clinical viability and deferring scale-up of operations until completion of PoC.
The unit relies on external networks of experts and service providers, and work is coordinated through proprietary software systems. Bodick’s presentation will review the numerous positive and negative PoCs that have been achieved in the first three years of operation as well as productivity gains relative to industry standard.
The 3rd Modern Drug Discovery & Development Summit features over 150 speakers participating in 6 concurrent conferences, 6 study sessions and 3 pre-conference workshops. Tracks include Biological Therapeutics, Drug Delivery Technology, Translational Medicine, Drug Design and Lead Optimization, Emerging Targets, and Pharmaco – Kinetics, Dynamics, Genomics and Genetics. For more information, visit www.gtcbio.com.
About GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Their goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, raniah@gtcbio.com
###
At M3D, Bodick will discuss one of Eli Lilly’s business units, Chorus, and its experience in early phase drug development. Chorus, a part of Lilly Research Laboratories, develops new chemical entities from candidate selection to clinical Proof of Concept (PoC), conducting minimal amount of work to demonstrate clinical viability and deferring scale-up of operations until completion of PoC.
The unit relies on external networks of experts and service providers, and work is coordinated through proprietary software systems. Bodick’s presentation will review the numerous positive and negative PoCs that have been achieved in the first three years of operation as well as productivity gains relative to industry standard.
The 3rd Modern Drug Discovery & Development Summit features over 150 speakers participating in 6 concurrent conferences, 6 study sessions and 3 pre-conference workshops. Tracks include Biological Therapeutics, Drug Delivery Technology, Translational Medicine, Drug Design and Lead Optimization, Emerging Targets, and Pharmaco – Kinetics, Dynamics, Genomics and Genetics. For more information, visit www.gtcbio.com.
About GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Their goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, raniah@gtcbio.com
###
Contact
GTCbio
Rania Hafez
626-256-6405
www.gtcbio.com
Rania Hafez
626-256-6405
www.gtcbio.com
Contact
Categories